I'm LongbridgeAI, I can summarize articles.Johnson & Johnson shares rose 1.2% to $274.395 after UBS raised its price target from $280 to $320, maintaining a Buy rating. UBS cited strong Q2 sales growth of 6.6% and raised 2026 sales guidance. Despite the upgrade, J&J trades significantly above its intrinsic value, requiring successful clinical and regulatory outcomes to justify further gains.
Johnson & Johnson , the pharmaceutical and medical-technology powerhouse, surged roughly 1.2% to $274.395 Wednesday after UBS cranked its price target from $280 to $320. Barron's reported that J&J became the Dow's biggest point booster in early trading. Wall Street heard the message loud and clear: UBS sees more fuel in this rally.
The firm kept its Buy rating, pointing to faster growth and more value hiding inside J&J's pharmaceutical pipeline. The operating engine is already delivering. J&J's second-quarter results showed sales climbing 6.6% to $25.3 billion, while management raised its 2026 sales midpoint to $101.1 billion and adjusted earnings guidance to $11.68 per share.
But the valuation is flashing yellow. The picture shows J&J trading 42.25% above its $192.90 GF Value, leaving little room for pipeline stumbles. UBS's $320 target still points to roughly 16.6% upside from $274.395, but J&J must earn every dollar. Clinical wins, regulatory approvals and successful launches now matter more than another round of multiple expansion.